Rohto Pharmaceutical CoLtd Performance
| RPHCFDelisted Stock | USD 14.72 0.00 0.00% |
The company holds a Beta of 0.5, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Rohto Pharmaceutical's returns are expected to increase less than the market. However, during the bear market, the loss of holding Rohto Pharmaceutical is expected to be smaller as well. Rohto Pharmaceutical right now holds a risk of 0.0%. Please check Rohto Pharmaceutical jensen alpha, as well as the relationship between the potential upside and rate of daily change , to decide if Rohto Pharmaceutical will be following its historical price patterns.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Rohto Pharmaceutical CoLtd has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable fundamental indicators, Rohto Pharmaceutical is not utilizing all of its potentials. The current stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
| Begin Period Cash Flow | 52.3 B | |
| Total Cashflows From Investing Activities | -16.4 B |
Rohto |
Rohto Pharmaceutical Relative Risk vs. Return Landscape
If you would invest 1,472 in Rohto Pharmaceutical CoLtd on October 15, 2025 and sell it today you would earn a total of 0.00 from holding Rohto Pharmaceutical CoLtd or generate 0.0% return on investment over 90 days. Rohto Pharmaceutical CoLtd is currently producing negative expected returns and takes up 0.0% volatility of returns over 90 trading days. Put another way, 0% of traded pink sheets are less volatile than Rohto, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Rohto Pharmaceutical Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Rohto Pharmaceutical's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Rohto Pharmaceutical CoLtd, and traders can use it to determine the average amount a Rohto Pharmaceutical's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| High Returns | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| RPHCF |
Based on monthly moving average Rohto Pharmaceutical is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Rohto Pharmaceutical by adding Rohto Pharmaceutical to a well-diversified portfolio.
Rohto Pharmaceutical Fundamentals Growth
Rohto Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Rohto Pharmaceutical, and Rohto Pharmaceutical fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Rohto Pink Sheet performance.
| Return On Equity | 0.13 | |||
| Return On Asset | 0.0696 | |||
| Profit Margin | 0.11 % | |||
| Operating Margin | 0.14 % | |||
| Current Valuation | 3.27 B | |||
| Shares Outstanding | 228.14 M | |||
| Price To Earning | 25.85 X | |||
| Price To Book | 2.57 X | |||
| Price To Sales | 0.02 X | |||
| Revenue | 199.65 B | |||
| EBITDA | 35.87 B | |||
| Cash And Equivalents | 77.26 B | |||
| Cash Per Share | 677.27 X | |||
| Total Debt | 13.35 B | |||
| Debt To Equity | 0.11 % | |||
| Book Value Per Share | 877.16 X | |||
| Cash Flow From Operations | 27.25 B | |||
| Earnings Per Share | 0.77 X | |||
| Total Asset | 274.63 B | |||
About Rohto Pharmaceutical Performance
By analyzing Rohto Pharmaceutical's fundamental ratios, stakeholders can gain valuable insights into Rohto Pharmaceutical's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Rohto Pharmaceutical has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Rohto Pharmaceutical has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
,Ltd. manufactures and markets pharmaceutical products, cosmetics, and functional foods worldwide. ,Ltd. was founded in 1899 and is headquartered in Osaka, Japan. Rohto Pharmaceutical operates under Household Personal Products classification in the United States and is traded on OTC Exchange. It employs 6866 people.Things to note about Rohto Pharmaceutical performance evaluation
Checking the ongoing alerts about Rohto Pharmaceutical for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Rohto Pharmaceutical help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Rohto Pharmaceutical is not yet fully synchronised with the market data | |
| Rohto Pharmaceutical has a very high chance of going through financial distress in the upcoming years | |
| About 13.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Rohto Pharmaceutical's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Rohto Pharmaceutical's stock is overvalued or undervalued compared to its peers.
- Examining Rohto Pharmaceutical's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Rohto Pharmaceutical's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Rohto Pharmaceutical's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Rohto Pharmaceutical's pink sheet. These opinions can provide insight into Rohto Pharmaceutical's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Other Consideration for investing in Rohto Pink Sheet
If you are still planning to invest in Rohto Pharmaceutical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Rohto Pharmaceutical's history and understand the potential risks before investing.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |